Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD)
M Ruospo, SC Palmer, P Natale… - Cochrane Database …, 2018 - cochranelibrary.com
Background Phosphate binders are used to reduce positive phosphate balance and to lower
serum phosphate levels for people with chronic kidney disease (CKD) with the aim to …
serum phosphate levels for people with chronic kidney disease (CKD) with the aim to …
[HTML][HTML] Management of hyperphosphatemia in end-stage renal disease: a new paradigm
A Rastogi, N Bhatt, S Rossetti, J Beto - Journal of Renal Nutrition, 2021 - Elsevier
Bone and mineral metabolism becomes dysregulated with progression of chronic kidney
disease (CKD), and increasing levels of parathyroid hormone serve as an adaptive …
disease (CKD), and increasing levels of parathyroid hormone serve as an adaptive …
Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis
R Brignardello-Petersen, A Bonner… - Journal of clinical …, 2018 - Elsevier
This article describes conceptual advances of the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) working group guidance to evaluate …
Assessment, Development, and Evaluation (GRADE) working group guidance to evaluate …
Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications
Abstract Chronic Kidney Disease (CKD) is linked to a rising prevalence of morbidity and
mortality primarily from cardiovascular complications and is considered a high or very high …
mortality primarily from cardiovascular complications and is considered a high or very high …
Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD
Background Benefits of phosphate-lowering interventions on clinical outcomes in patients
with CKD are unclear; systematic reviews have predominantly involved patients on dialysis …
with CKD are unclear; systematic reviews have predominantly involved patients on dialysis …
Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
M Cozzolino, A Galassi, F Conte… - … and clinical risk …, 2017 - Taylor & Francis
Secondary hyperparathyroidism (SHPT), a very frequent, severe, and worsening
complication of chronic kidney disease, is characterized by high serum parathyroid hormone …
complication of chronic kidney disease, is characterized by high serum parathyroid hormone …
Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta …
K Chaiyakittisopon, O Pattanaprateep… - The European Journal of …, 2021 - Springer
Background Uncontrolled hyperphosphatemia in chronic kidney disease (CKD) patients
commonly results in vascular calcification leading to increased risk of cardiovascular …
commonly results in vascular calcification leading to increased risk of cardiovascular …
[HTML][HTML] Application of network meta-analysis in the field of physical activity and health promotion
Continued advancement in the field of physical activity and health promotion relies heavily
on the synthesis of rigorous scientific evidence. As such, systematic reviews and meta …
on the synthesis of rigorous scientific evidence. As such, systematic reviews and meta …
[HTML][HTML] Recomendaciones del grupo GARIN para el tratamiento dietético de los pacientes con enfermedad renal crónica
MR Alhambra-Expósito, MJ Molina-Puerta… - Nutricion …, 2019 - SciELO Espana
Resultados: la actuación terapéutica debe ser individualizada y atendiendo al grado de
enfermedad renal que presente el paciente ya sus comorbilidades. En cuanto a la terapia …
enfermedad renal que presente el paciente ya sus comorbilidades. En cuanto a la terapia …
磷酸盐保水机理及其对水产品保水作用的研究进展.
郭祉含, 王嵬, 贾志慧, 仪淑敏… - Journal of Food …, 2020 - search.ebscohost.com
磷酸盐是目前国内外应用最广泛的食品保水剂之一, 磷酸盐及其复配产品常应用在水产品加工
以及贮藏过程中, 以提高水产品的保水性, 最大限度减少水分, 风味物质及营养成分的流失 …
以及贮藏过程中, 以提高水产品的保水性, 最大限度减少水分, 风味物质及营养成分的流失 …